GeneDx Holdings Corp. · Healthcare
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 5.0% margin the price requires 26.9% 3y revenue CAGR against 18.4% consensus, a cushion of -26.2pt versus a 0pt correction cut. Price needs more growth than consensus at any nearby discount rate, so the correction has room to go further. High-beta multiple; the risk is reimbursement, not AI.
Would recover if: reimbursement per test keeps falling ($3,500 to $3,300). We re-check this against analyst estimates every evening.
10 years, at a 5% margin analysts expect
+11.9%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
8 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. Two or more red flags: this name cannot come out on top, however large its cushion.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Aug 27, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The current price sits at the very top of the published analyst target range ($63 to $90), fully endorsing the most optimistic models and explicitly rejecting the five lower targets that assume the recent drop in average reimbursement rates is a permanent shift.
Will the average reimbursement rate per test recover toward $3,500, or will the adverse shift toward lower-ARR genome tests keep it near $3,300? The wired data can measure segment revenue volumes to track the exome-to-genome mix shift, but it cannot directly measure the average reimbursement price.
What the price refuses to pay for, and the full reconstruction, on the WGS quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names